About us

We are entering an exciting era in which disease-modifying treatments are becoming a reality for brain diseases that are currently untreatable, such as Alzheimer’s and Huntington’s Diseases (HD), or limited to symptomatic approaches, such as Parkinson’s Disease (PD) and many forms of epilepsy. Many of the most promising emerging treatments use Advanced Therapeutic Medicinal Products (ATMPs), which involve delivering genes, RNA, or cells directly into the brain.  

The Advanced Neurotherapies Centre is one of only a few centres worldwide with the research capacity to address the translational challenges of intracranial delivery by developing and investing in “Delivery Science” and de-risking First in Human trial transition using human tissue. We prioritise Delivery Science for improving and quantifying clinical trial ATMP delivery, as the greater need and opportunity for impact.    

• Find out more about our research.
• Meet our team.

We receive core funding from Welsh Government through Health and Care Research Wales, Advanced Therapies Wales and Midland Wales Advanced Therapies Treatment Centre.  

From our inception in 2015 to 2025, we were known as the Brain Repair and Intracranial Neurotherapeutics (BRAIN) Unit, focusing on developing novel therapeutics and treatment delivery systems for neurological conditions.